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INTRODUCTION
Epstein-Barr virus (EBV) is present within the malignant lymphocytes of most endemic
Burkitt lymphomas, nasal T/NK lymphomas, and lymphomas arising in patients with
primary or iatrogenic immune deficiencies, and is also associated with a subset of sporadic
B and T cell lymphomas.(1) The laboratory assay typically used to classify a tumor as being
EBV-related is EBV-encoded RNA in situ hybridization, since EBER is expressed in
latently infected cells and this assay can localize the infection to the malignant cell
population.(1) Immunohistochemical stains are used to localize expressed viral proteins to
tumor cells, but the spectrum of viral protein expression differs among tumor types and so
there is concern for false negative test results. A tumor clone harboring a partially deleted
EBV genome could go undetected by expression-based assays if the loss of genetic material
results in atypical patterns of EBV gene expression.
Partially deleted or rearranged EBV DNA has been identified in some EBER-negative
sporadic Burkitt lymphomas, which suggests that EBV DNA (or remnants of the EBV
genome) may be present in a greater proportion of lymphomas than previously assumed.(2,
3) Prior molecular characterization of infected lymphomas identified two AIDS-related
lymphomas with false negative tests for selected segments of the EBV genome, one of
which had selective deletion of LMP2 gene sequences, and another with selective dropout of
BZLF1 and LMP1 amplicons.(4) Molecular characterization of infected gastric
adenocarcinomas revealed an infected tumor with amplifiable LMP1 but lacking 5 other
segments of the viral genome that were queried by quantitative polymerase chain reaction
(Q-PCR).(5) These examples suggest that tumors with atypical viral genomes may elude
detection by commonly used laboratory assays, and raise the question of whether remnants
of the viral genome are present in tumor subtypes that have not previously been associated
with viral infection.
Beyond the potential for interference with laboratory tests, viral gene polymorphism could
impact viral pathogenicity. Variants in the EBV genes LMP1, EBNA2, EBERs, and BARF1
are reportedly more common in infected tumors than in geographically matched non-tumor
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control subjects.(6–12) Research into the clinicopathologic significance of these
polymorphisms is facilitated by cataloging viral genomic variants in public databases such
as the Virus Pathogen Resource at www.viprbrc.org.
In the current study we used a battery of real-time Q-PCR assays to amplify six disparate
segments of the EBV genome (LMP2, EBER1, BamH1W, BZLF1, EBNA1, and LMP1) in
non-Hodgkin lymphomas of varying histologic subtypes. Tumors with measurable viral
loads or EBER localization to malignant cells by in situ hybridization were further studied
using a panel of immunohistochemical stains to characterize LMP1 expression (associated
with latent EBV infection) and BZLF1 and BMRF1 expression (associated with lytic EBV
infection). Our goal was to evaluate a wide range of lymphoma subtypes for evidence of
segmental viral genomic deletion, which has implications for etiologic mechanisms of viral




Archival paraffin-embedded tumor tissue from 107 patients was retrieved from the clinical
files of hospitals affiliated with the University of North Carolina and the University of
Vermont. Tumors were selected to represent a spectrum of non-Hodgkin lymphoma
subtypes, including lymphomas commonly associated with EBV (peripheral T cell
lymphoma, diffuse large B cell lymphoma, and Burkitt lymphoma) as well as subtypes not
usually associated with EBV (follicular lymphoma, marginal zone lymphoma including
mucosa-associated lymphoid tumor (MALT), mantle cell lymphoma, and small lymphocytic
lymphoma). Experienced hemtopathologists (CD, RB, and YF) confirmed that tumor was
present in each sample and corroborated the histologic subtype using World Health
Organization criteria.(13) This study was done with approval of the Institutional Review
Board.
Quantitative real-time PCR
Q-PCR assays targeted and quantified six disparate regions of the EBV genome (Figure 1)
in DNA extracted from two 10-micrometer thick paraffin sections cut from archival blocks,
as previously described.(4, 5) All six Q-PCRs (for BamH1W, EBNA1, LMP1, LMP2,
EBER1, and BZLF1 segments) were previously validated on dilutions of cell line DNA and
on paraffin embedded malignant tissues of known EBV status.(4, 5) One lymphoma with
evidence of selective dropout of BamH1W amplicons was subjected to an alternate Q-PCR
assay for the BamH1W region developed by Lo et al.(14) The alternate Q-PCR assay was
validated by showing that viral loads measured using the alternate assay were equivalent to
viral loads measured using our primary BamH1W Q-PCR assay when both assays were
applied to 5 EBER-positive and 5 EBER-negative lymphomas.
For all six Q-PCRs, BLAST sequence analysis indicated no significant primer or probe
homology with human DNA or other herpesvirus genomes. Cross reactivity with other
herpesviruses was further examined by running each Q-PCR on purified cytomegalovirus
(CMV), HHV8 (Kaposi’s sarcoma associated herpesvirus, KSHV), varicella zoster virus
(VZV) and herpes simplex virus (HSV1) DNA; formalin-fixed paraffin-embedded tissue
from five patients diagnosed with other herpes family viruses (three with CMV, two with
herpes simplex); and a paraffin-embedded pellet of the EBV-negative BL30 human
lymphoma cell line.
PCR and product detection was performed on an ABI Prism 7500 Real-Time PCR
instrument with Sequence Detection System software (Applied Biosystems, Foster City,
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CA). Thermocycling conditions were: 50°C for 2 minutes and 95°C for 10 minutes,
followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Each 25uL reaction
contained 1X TaqMan Universal Master Mix, TaqMan probe (10pmoL), and 1uL of DNA
template. Assays targeting LMP1 and BZLF1 used 30pmoL of forward and reverse primers,
while all other assays used 15pmoL of each primer. Standard curves were generated for each
assay using serial 10-fold dilutions of Namalwa Burkitt lymphoma DNA (cell line from
American Type Culture Collection, Rockville, MD) having two copies of the EBV
genome(15) and two copies of the APOB human control gene per cell. Standard curves were
deemed acceptable if they demonstrated analytic sensitivity to 50 or fewer copies of EBV
DNA, a difference of 3.3 +/− 0.3 cycles between 10-fold dilutions, and a correlation
coefficient of at least 0.99. Q-PCR of a segment of the human APOB gene was used to
confirm the efficacy of DNA extraction and to calculate the number of cells amplified per
reaction. Samples with fewer than 40 cells (as measured by Q-PCR targeting human APOB
against a Namalwa cell line standard) were retested for APOB and for all six EBV DNA
targets at higher or lower template volumes, and samples with consistently low APOB levels
were excluded from further analysis.
To check for amplicon contamination, every run contained at least two “no template”
controls in which nuclease-free H2O was substituted for template. All experimental samples
were run in duplicate, and mean viral loads were calculated based on the ratio of EBV to
APOB copies in a given volume of extracted DNA, expressed as the number EBV DNA
copies per 100,000 cells. Samples with no measurable EBV DNA were reported as having
viral loads of zero.
Paraffin-embedded cell lines
Well described EBV-infected cell lines were fixed, embedded in paraffin, and tested by the
battery of six EBV Q-PCRs. The B95-8 lymphoblastoid cell line is reported to harbor both
episomal and replicative EBV genomes.(16) Chromosomal integration of the viral genome
in Namalwa Burkitt lymphoma, BL30-B95-8 superinfected Burkitt lymphoma, and IB4
lymphoblastoid B cell lines affects the terminal repeat structure(17–19) which could disrupt
LMP2 reading frames, possibly interfering with intracellular signaling and lytic viral
replication. Raji Burkitt lymphoma cells are reported to harbor a mixture of episomal and
integrated genomes, with integration affecting the structure of the BamH1W-Y region.(20)
The BL30-P3HR1 superinfected Burkitt line harbors the P3HR1 strain of EBV, which has
multiple genomic variations (e.g. deletions, mutations) compared with the prototypic B95-8
strain.(21, 22)
Each cell line was grown in standard culture conditions, and cell pellets were fixed in 10%
buffered formalin and then suspended in low-melting temperature agarose or fibrin clots
prior to embedding in paraffin. Total DNA was extracted from paraffin sections, and EBV
DNA was amplified by the same methods used for patient samples. The Namalwa cells that
were paraffin embedded had been serially passaged for several years, whereas fresh
Namalwa cell line DNA was used for assay calibration. To verify the linearity and
sensitivity of each Q-PCR assay, we performed Q-PCR on serial ten-fold dilutions of
template DNA extracted from paraffin-embedded Namalwa and Raji cell line samples with
known EBV copy numbers (2 copies and about 55 copies of EBV DNA per cell,
respectively).(15, 20, 23, 24)
EBV-encoded RNA (EBER) in situ hybridization
Each tumor was assayed for latent EBV infection by EBER in situ hybridization performed
on an automated system that utilized fluorescein-labeled EBER probe and colorimetric
detection (Ventana Benchmark, Ventana Medical Systems, Tucson AZ). A parallel
Tang et al. Page 3













hybridization using oligo(d)T probe served as a control for RNA preservation. A molecular
hematopathologist (MLG) classified tumors as EBER-positive if the EBER signal was
localized to malignant appearing cells, or as EBER-negative if the signal was undetectable
or was localized only to benign cells.
Immunohistochemistry for viral LMP1, BMRF1, and BZLF1 proteins
Immunohistochemical assays to detect expression of selected viral proteins were performed
on paraffin sections of all lymphoma tissues that were EBER-positive or had measurable
EBV DNA by any of the six Q-PCR assays. EBV LMP1 staining was done as previously
described(4) using citrate retrieval and the anti-EBV LMP1-clone CS1-4 cocktail of mouse
monoclonal antibodies (1:100, Dako, Carpinteria, CA). Immunohistochemical detection of
the EBV replicative proteins BMRF1 and BZLF1 was performed using citrate retrieval and
anti-BMRF1 clone G3-E31 (1:200 dilution, Research Diagnostics, Inc., Flanders, NJ) or
anti-BZLF1 clone BZ.1 (1:25 dilution, Dako, Carpinteria, CA), with primary antibody
treatment for 30 minutes at 37°C. The Super-Sensitive Non Biotin HRP Detection Kit with
diaminobenzidine chromogen (Biogenex, San Ramon, CA) was used for blocking and
detection. Tissues were counter-stained with hematoxylin (Dako, Glostrup, Denmark) and
interpreted for signal localization to tumor cells. Positive controls were a known EBV-
related Hodgkin lymphoma (for LMP1) and an oral hairy leukoplakia (for BMRF1 and
BZLF1).
Statistical analyses
Means and standard deviations were compared to determine concordance of viral load
measurements across the six Q-PCR assays, and to identify atypical EBV-positive cases as
assessed by evidence of selective failure of one or more Q-PCR assays in a given case. We
used receiver operating characteristic (ROC) analyses(25) to evaluate Q-PCR viral load
threshold as a method for distinguishing between tumors with neoplastic versus non-
neoplastic (incidental) EBV infection (as defined by the gold standard EBER in situ
hybridization). This was accomplished by plotting the true positive rate against the false
positive rate when various viral load thresholds were applied, and calculated area under the
curve (AUC) was used to estimate the proportion of paired neoplastic and non-neoplastic
samples that would be classified correctly for each viral load threshold. All p-values
reported for statistical tests of differences in means and proportions are two-sided.
RESULTS
EBV DNA measurements by Q-PCR in infected or uninfected lymphoid cell lines
EBV copy numbers in serially diluted paraffin-embedded Namalwa and Raji cell lines
demonstrated that all six Q-PCR assays were sensitive to fewer than 50 copies per PCR, and
were linear over at least 3 orders of magnitude. No amplification was seen when pure viral
DNA samples of CMV, HHV8, VZV or HSV1 were used as the template for Q-PCR assays
(Table 1). Amplification was also negative in the EBER-negative BL30 human cell line and
the two HSV-positive patient samples. All three CMV-related colon lesions had low levels
of EBV DNA detected by at least two independent Q-PCR assays, but no amplification was
observed with purified CMV DNA; therefore, we concluded that the weak EBV signal in the
CMV-positive biopsies reflected true EBV DNA presence, which is not unexpected in
human tissue samples given the ubiquitous prevalence of EBV infection in adults. In total,
these findings suggest no cross reactivity of the six EBV Q-PCR assays with any of the
other herpesvirus family members tested.
If each infected cell line contains only intact EBV genomes (without segmental deletions or
gene amplifications), we would expect comparable viral load estimates across all of the Q-
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PCR assays except the assay for BamH1W, a known repeat sequence.(4, 5) However, we
observed some discrepancies among the six viral loads in most cell lines (Table 2). In four
of the cell lines (Namalwa, Raji, B95-8, and BL30-B95-8) there was a >9-fold difference
between the lowest and highest viral load estimate (e.g., ranging from 112 copies of LMP2
to 1,265 copies of LMP1 DNA in the BL30-B95-8 cell line) whereas there was less than a 5-
fold difference in viral loads for the two remaining cell lines (IB4 and BL30-P3HR1, with
viral loads ranging from 1 – 3 and 2 – 9 copies per cell, respectively). A noticeable trend is
that LMP2 values copy numbers were relatively low compared with copy numbers of the
other EBV gene segments, which could indicate a problem with assay calibration or assay
efficiency for the LMP2 gene segment. Alternatively, it could indicate that the LMP2
segment was consistently defective (e.g. deleted or mutated) in a way that interfered with its
enumeration in each cell line, but this explanation seems less plausible because LMP2 copy
numbers were also relatively low in the naturally infected lymphomas as described below.
The Namalwa cell line is reported to have two integrated copies of the EBV genome per cell
(15). We confirmed two copies (plus or minus one copy) per cell in paraffin-embedded
samples of Namalwa cells based on LMP2, EBER1, BZLF1, EBNA1 and LMP1 assays
(Table 2). In contrast, we measured 24 copies per cell of the BamH1W segment, a tandem
repeat sequence with varying copy numbers across strains of EBV. Copy numbers of tandem
repeat segments have been reported to fluctuate during long-term cell culture and during
lytic viral replication.(26) When the BamH1W and LMP2 regions are excluded from
consideration, copy numbers based on the remaining four Q-PCR assays were equivalent
(within about a one log range) in all six cell lines.
Q-PCR and EBER in situ hybridization results in patient samples
Nine patient tumors were excluded from further analyses because of inadequate tissue (5
MALT lymphomas), inadequate APOB amplification (2 diffuse large B cell lymphomas), or
missing histologic subtype data (2 tissues), leaving 98 unique archival paraffin-embedded
human lymphoma samples that were evaluable by Q-PCR, EBER in situ hybridization, and
at least 2 immunohistochemical assays (Table 3).
PCR assays were negative for all six EBV segments in 50 samples and positive for at least
one EBV segment in 48 samples. Mean estimated APOB copy numbers were comparable
between PCR-negative and PCR-positive cases (PCR negative: 8,105 copies / PCR, 95%
confidence interval (CI) 5,363-10,847; PCR positive: 7,223 copies / PCR, 95% CI 4,700 –
9,746; p = 0.6). All 50 PCR-negative samples were also EBER in situ hybridization
negative.
Thirty-eight PCR-positive tumors were classified as non-neoplastic (incidental) EBV
infections based on lack of localization to malignant cells by EBER in situ hybridization
(Table 3). Only three of these tumors had amplification of all six EBV segments (Table 4).
BamH1W was the most common target amplified from these samples (n=30/38 tissues
positive), with a mean copy number of 119 EBV copies/100,000 cells (range 1 – 870). PCR-
positive/EBER-negative samples were identified among all histologic subtypes, but were
most common among the marginal zone lymphomas (10 of 15 samples, including 9 of the
14 subclassified as MALT) and mantle cell lymphomas (2 of 3 samples).
The 10 remaining PCR-positive samples were classified as neoplastic EBV infections based
on EBER localization to malignant cells by in situ hybridization (4 Burkitt, 3 diffuse large B
cell, and 3 T-cell lymphomas). Six of these PCR-positive/EBER-positive samples had high
copy numbers for all EBV target segments and were classified as “typical” neoplastic
infections (Table 5). The remaining 4 were classified as “atypical” infections because at
least one EBV segment failed to amplify or was amplified at a relatively low level (at least
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10-fold lower than the next highest value). These included one diffuse large B cell
lymphoma with virtually no amplification of BamH1W, BZLF1 or EBNA1, and three T-cell
lymphomas with little or no amplification for LMP2. All 4 atypical samples amplified
LMP1 and EBER1 (the latter in keeping with positive EBER in situ hybridization results).
Mean copy numbers were lower for EBV targets amplified from atypical versus typical
EBV-positive lymphomas, but were nonetheless 27 – 223 times higher than corresponding
mean copy numbers for EBV targets amplified in PCR-positive/EBER-negative samples.
EBV protein expression
Immunohistochemical assays aimed at localizing lytic (BZLF1 and BMRF1) or latent
(LMP1) EBV infection to neoplastic cells were negative in all 43 PCR-positive/EBER-
negative samples tested. Five additional samples could not be assayed for LMP1 protein
because tissue had been exhausted.
Among the ten EBER-positive tumors (Table 5), immunohistochemistry results varied. Two
of six samples classified as typical infections expressed both BZLF1 (a sign of early lytic
viral replication) and BMRF1 (a sign of active lytic replication), while another expressed
only BZLF1, and none expressed LMP1. Two of four samples classified as atypical EBV
infections expressed all three viral proteins (LMP1, BZLF1 and BMRF1). BZLF1 protein
expression was negative in the atypical sample having evidence of BZLF1 amplicon
dropout, but this is not necessarily attributable to gene deletion as staining was also negative
in 4 samples with high levels of BZLF1 DNA. In all samples with visible EBV protein
expression, expression was limited to a small proportion of neoplastic cells. In contrast,
EBER was expressed in virtually all malignant cells.
Q-PCR can identify neoplastic EBV infections
ROC analyses were performed on Q-PCR data from 10 PCR-positive/EBER-positive and 38
PCR-positive/EBER-negative lymphomas to identify the viral load threshold that best
distinguished neoplastic EBV infection from incidental EBV infection (Table 6). Neoplastic
infection was identified with 100% sensitivity when 500 or more copies of EBER1 or LMP1
segments were amplified, whereas sensitivity at this copy number threshold was only 90%
for BamH1W, BZLF1, and EBNA1 segments, and only 80% for LMP2. These results reflect
the low or negative amplification of certain EBV targets in atypical EBER-positive tumors
(case #2681 with fewer than 500 copies of BamH1W, EBNA1, and BZLF1, and cases #2778
and #2783 with fewer than 500 copies of LMP2). However, the 500 copy number threshold
was sufficient to identify neoplastic (EBER-positive) infections for all six EBV genomic
targets when the 4 samples classified as atypical neoplastic infections were excluded.
False positive classification rates decreased as the copy number threshold was increased, so
that all incidentally infected cases were classified correctly when a 2,000 minimum copy
number threshold was applied (Table 6). All neoplastic and incidentally infected cases were
correctly classified using a 2000 copy number threshold for EBER1 or LMP1. Because of
the atypical infection cases, only 95% of cases were correctly classified (AUC 95% CI 85 –
100%) using a 2,000 copy number threshold for BamH1W, BZLF1, or EBNA1, and 85% of
cases were correctly classified (AUC 95% CI 70 – 100%) for LMP2. Overall these data
suggest that use of EBER1 or LMP1 Q-PCR assays exceeding a threshold of 2,000 copies
per 100,000 cells would be a reasonable strategy to screen lymphomas for neoplastic EBV
infection.
Clinical characteristics
Age at diagnosis was available for 91 cases and gender was known for 93 cases. Age was
similar for patients with PCR-positive and PCR-negative lymphomas (57 years, 95% CI 51
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– 63 versus 52 years, 95% CI 46 – 58, p = 0.2) but was lower for patients with PCR-
positive/EBER-positive lymphomas than PCR-positive/EBER-negative tumors (46 years,
95% CI 33 – 60 versus 59 years, 95% CI 52 – 66, p = .08). Clear gender differences were
not apparent, but patients with PCR-positive lymphomas were somewhat more likely to be
male than patients with PCR-negative tumors (74% versus 64%, p = 0.3) and patients with
PCR-positive/EBER-positive tumors were more likely to be male than those with PCR-
positive/EBER-negative tumors (80% versus 72%, p = 0.6). Pathology reports suggested
that 4 cases were in immunocompromised patients, including 2 PCR-negative Burkitt
lymphomas, 1 PCR-positive/EBER-negative diffuse large B cell lymphoma, and 1 PCR-
positive/EBER-positive Burkitt lymphoma classified as a typical neoplastic infection.
Clinical characteristics should be interpreted with caution given that our study included a
small convenience sample of cases.
Case report of an atypical EBV-infected lymphoma
One atypical EBER-positive lymphoma (case #2681 in Table 5) had little or no
amplification of BamH1W, EBNA1, and BZLF1, but relatively high levels LMP2, EBER1,
and LMP1 (1,745, 13,908 and 92,558 copies per 100,000 cells). These findings are
consistent with deletion of the middle section of the viral genome with retention of both
ends. All Q-PCR assays were repeated at least four times to confirm the viral loads for this
tumor. Negative results for the BamH1W segment were confirmed using both primer/probe
sets targeting the BamH1W portion of the EBV genome.
This tumor was a diffuse large B cell lymphoma arising in a 53 year old Hispanic female.
The patient presented with a 3 month history of sore throat, bilateral parotid swelling, and
cervical lymphadenopathy. She underwent bilateral tonsillectomy to relieve partial tracheal
obstruction. Histologic examination of tonsil tissue revealed sheets of large cells with folded
or cleaved nuclei and vesicular chromatin (centroblastic polymorphous appearance).
Immunohistochemistry showed expression of CD45 (weak), CD20, CDw75, CD79a, BCL6,
and BCL2. The large cells did not express CD10, MUM1, CD138, CD23, TdT, or CD34.
CD5 and CD3 stained similar numbers of scattered small benign-appearing lymphocytes. By
flow cytometry, the large cells expressed CD71 with dim CD45 and co-expression of CD20
and CD19 with no associated light chain expression or expression of CD10 or CD23.
Karyotype showed t(14;18) IGH/BCL2 in addition to complex chromosomal abnormalities:
46X,der(X)t(x;1)(p11.2;q25),t(1;3)(q?24;q27),add(2)(p21),t(14;18)
(q32;q21),der(18)t(14;18)(q32;q21)[20]/ 47,idem,+21[5]. The tumor was subclassified as a
malignant lymphoma, diffuse large B cell type, germinal center subtype (follicle center cell
origin). HIV serology was negative. The patient responded well to six cycles of
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab
followed by involved field radiation to the head and neck. The clinicopathologic findings in
this case are not unusual for a lymphoma of this subtype, except for the atypical EBV
genomic structure.
DISCUSSION
This study is the first to test for multiple segments of EBV DNA in a wide spectrum of non-
Hodgkin lymphoma tissues. EBV was detected only in lymphoma subtypes that are already
known to be EBV-related (Burkitt, diffuse large B cell, and T cell), and there was no
evidence of EBV DNA remnants in other lymphoma subtypes (follicular, marginal zone,
small lymphocytic, mantle cell). High EBV DNA copy numbers were found only in
lymphomas classified as neoplastic EBV infections based on standard EBER in situ
hybridization. Correlation between viral load and EBER localization supports the efficacy of
quantitative (as opposed to qualitative) DNA amplification as a screening test for EBV-
related malignancy. Occasional false negative Q-PCR results reinforce the utility of EBER
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in situ hybridization as the gold standard assay for detecting tumor-associated EBV and for
defining a tumor as EBV-related.
Low level EBV DNA (based on Q-PCR amplification of one or more EBV targets) was
found in some lymphoma tissues despite the absence of latent (EBER, LMP1) or lytic
(BZLF1 or BMRF1) viral gene expression, consistent with incidental infection of rare
benign lymphoid cells. Interestingly, four EBER-positive tumors had evidence of selective
drop out of portions of the EBV genome, suggesting genomic deletion or mutation involving
BamH1W, EBNA1, BZLF1 or LMP2 gene segments. One of the four was a diffuse large B
cell lymphoma with almost complete loss of amplicons in the central portion of the EBV
genome (BamH1W, EBNA1 and BZLF1). The remaining three cases were T cell
lymphomas with marked, selective reduction of LMP2 amplicons, implying that LMP2 gene
defects may be common in infected T cell tumors.
In prior studies, selective loss of BZLF1, LMP1 or LMP2 amplicons was identified in a
fraction of AIDS lymphomas,(4) and selective loss of LMP2 was found in a gastric
adenocarcinoma.(4, 5) Another unusual gastric adenocarcinoma had loss of all but the
LMP1 amplicon, but it was not possible to determine whether this tumor contained only a
small segment of the EBV genome, or if the LMP1 amplification was false positive.(5) If the
EBER1 segment of the viral genome can be lost, then previous findings,(2–5) reinforced by
data from the present study, suggest that there is not a single Q-PCR that is completely
reliable for detecting tumor-associated EBV infection. This work has implications for the
design of assays to identify EBV-associated malignancy. Specifically, it suggests that
several disparate EBV gene segments should be assayed by Q-PCR, or that the gold standard
EBER in situ hybridization assay should be used to maximize the detection of EBV in all
types of malignancy.
Identifying EBV is important from a clinical standpoint since patients with EBV-infected
lymphomas may be candidates for novel or alternative therapies targeting virally infected
cells.(27–33) Indeed, progress has been made in treating EBV-related malignancies by
infusing EBV-specific cytotoxic T cells, by inducing lytic viral replication, and/or by
delivering drugs that leverage virus-driven biochemical pathways.
In clinical settings, Q-PCR of blood or plasma is frequently used to monitor tumor burden in
allogeneic transplant recipients or nasopharyngeal carcinoma patients.(1, 34) The high levels
of circulating EBV DNA in affected patients presumably derive from death of infected
tumor cells.(35) Evidence that selected Q-PCR amplicons may be lost in primary tumor
tissue implies that tumor-derived viral DNA in body fluids may also fail to amplify,
potentially adversely impacting the efficacy of viral load assays in clinical settings.
Consequently, it would be prudent to confirm amplification of EBV DNA in tumor tissue or
in body fluid at the time of initial diagnosis before using the same assay to amplify EBV
DNA in subsequent body fluid specimens as a marker of tumor burden.
Identifying and studying lymphomas with viral genomic deletion or mutation is relevant to
understanding oncogenesis, since a corrupted viral coding sequence could result in abnormal
viral gene expression affecting the tumorigenic potential of the viral strain. One remarkable
case of diffuse large B cell lymphoma (case #2681 in this study) had evidence suggesting
deletion of a large segment of the EBV genome. Assuming the deletion was contiguous
across the three relevant segments, viral DNA spanning multiple latent and lytic genes as
well as microRNA coding sequences would have been lost, resulting in altered
transcriptional regulation of both viral and cellular genes. If true, the result implies that these
EBV genome segments are not necessary to maintain EBV in lymphoma cells. EBV
persistence in the absence of EBNA1, a gene believed to be required for propagation of
Tang et al. Page 8













EBV DNA to daughter cells upon cell division,(36) suggests that episomal partitioning
during mitosis may be obviated, which in turn suggests that the residual viral genome is
integrated into host chromosomal DNA.
We used the Namalwa cell line as a standard for quantitative PCR because it has two
integrated copies of the EBV genome per cell. When our battery of Q-PCR assays was used
to measure viral genome copy number in a later passage of Namalwa cells and in five other
well-characterized cell lines, certain parts of each viral genome had varying copy numbers
that may have resulted from genetic polymorphism (mutation, deletion, gene amplification,
or integration into the human genome). Altered copy number of tandem repeat sequences is
a well described phenomenon, and it has been reported that numbers BamH1W repeat
sequences can vary during long term culture, and during viral replication.(26) With the
exception of the BamH1W repeat region, the remaining segments of the Namalwa genome
varied no more than two fold (one PCR cycle) from the expected value, which supports the
suitability of Namalwa as a standard for quantifying viral load. Similarly, the IB4 cell line,
known to have two integrated copies of the EBV genome, had six different viral loads
varying no more than two-fold (one PCR cycle) from the expected value. Given that these
cell lines were fixed and paraffin embedded prior to DNA extraction, the fairly consistent
viral loads measured in Namalwa and IB4 support the accuracy of EBV viral load
measurements by Q-PCR in fixed tumor tissues.
The Raji Burkitt lymphoma cell line had widely varying viral loads ranging from 2 to 74
copies per cell depending on which genomic segment was targeted by our battery of six Q-
PCRs. Prior work has identified both episomal and integrated EBV genomes in Raji cells,
and four recurrent integration sites.(37) The relatively low BamH1W copy number
measured in Raji cells in the present study could reflect viral genome disruption at the sites
of chromosome integration previously described by Gao et al.(37)
The B95-8 cell line is a lymphoblastoid cell line that contains the prototypic wild-type EBV
genome and demonstrates active lytic viral replication in a subset of infected cells. Our
battery of six Q-PCRs demonstrated consistent viral loads (within one log), and an average
viral load of 50 copies per cell. In the BL30-B95-8 cell line, a Burkitt lymphoma line
(BL30) superinfected with EBV B95-8 virions, our battery of Q-PCRs demonstrated
consistent viral loads (within one log), and an average load of 539 copies per cell. This high
load (compared with an average of 5 copies per cell in the prototypic B95-8 cell line from
which the virus is derived) implies that viral load is not determined by the strain of EBV
exclusively. Nor is the host cell the only factor influencing viral load given that the BL30-
P3HR1 line derived from the same BL30 parental line yielded much lower viral loads
(average 5 copies per cell).
Our Q-PCR assays may be useful to epidemiologists seeking cost-efficient and reliable
methods of detecting EBV-related tumors in large numbers of archival paraffin-embedded
patient samples. Our current data suggest that a viral load of >2,000 LMP1 or EBER1 copies
per 100,000 cells may be sufficient to identify neoplastic infections with 100% sensitivity
and specificity. However, prior work has shown assay interference for LMP1 or EBER1
amplification by virtue of viral genomic mutation or deletion.(4, 5) Therefore two or more
segments of the viral genome should be amplified to reduce the likelihood of a false
negative result. When testing for low-level EBV infection (such as minimal residual disease
after therapy), BamH1W appears to be the most sensitive of the Q-PCR assays,(1, 4, 5)
probably because it targets a reiterated sequence. The presence of at least 2,000 copies of
any EBV DNA segment is a reasonable surrogate for infected neoplasia, but confirmatory
testing by EBER in situ hybridization is necessary to demonstrate EBV localization to the
lesion of interest. Histochemical assays for BZLF1, BMRF1 or LMP1 protein expression do
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not appear to add value as part of a screening strategy for neoplastic infections, but they may
be useful for cancer diagnosis and classification.(1)
In conclusion, we have shown that a battery of Q-PCR assays is sensitive and specific for
detecting tumor-associated EBV in archival paraffin-embedded patient samples. Our
findings suggest that a threshold of 2,000 EBV copies per 100,000 cells can be used to
distinguish tumors with neoplastic versus incidental EBV infection. Evidence of viral
genome variation (such as point mutation, deletion, or chromosomal integration) in a subset
of cases is relevant to laboratory medicine practice and has implications for disease
pathogenesis. Atypical viral genome structure could interfere with certain assays aimed at
viral detection, emphasizing the need to target more than one viral genome segment in order
to maximize identification of infected tumors. Importantly, we did not identify any viral
genomic alteration that would have rendered a tumor-specific infection undetectable by
EBER in situ hybridization, which reinforces the role of EBER in situ hybridization as the
gold standard assay for defining EBV-related malignancy. Our study showed that among
EBER-negative tumors, there is scant evidence to support a hit-and-run hypothesis whereby
the virus was present during lymphomagenesis but then was partially eliminated, thus
retaining only remnants of the viral genome in malignant cells. Further work is needed to
precisely characterize viral genomic variants as facilitated by emerging next generation
sequencing strategies. Results should be correlated with clinicopathologic findings to shed
light on the oncogenic impact of atypical viral genomes.
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EBV genome map. BamH1 restriction enzyme cut sites shown above the map result in
fragments named from largest to smallest in alphabetical order, with lower case letters
following Z. Below the map are the locations of the six gene segments evaluated in this
study.
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